Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (OU-SCC-STAR)

NCT04068753 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT04068753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (OU-SCC-STAR)
Lead sponsor
University of Oklahoma
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 26, 2020
Completion date
July 31, 2027
Enrollment
66 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

progressive cervix cancer, recurrent cervix cancer